key: cord-0729906-q2z1c5eq
authors: Amin-Chowdhury, Zahin; Aiano, Felicity; Mensah, Anna; Sheppard, Carmen; Litt, David; Fry, Norman K; Andrews, Nick; Ramsay, Mary E; Ladhani, Shamez N
title: Impact of the COVID-19 Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal Coinfection with SARS-CoV-2: prospective national cohort study, England
date: 2020-11-16
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1728
sha: 25897ce9b40f1cb9e72c3ace0bd83842af0a3c5f
doc_id: 729906
cord_uid: q2z1c5eq

BACKGROUND: Streptococcus pneumoniae coinfection with influenza results in synergistic lethality, but there are limited data on pneumococcal coinfection with SARS-CoV-2. METHODS: Public Health England conducts invasive pneumococcal disease (IPD) and SARS-CoV-2 surveillance in England. IPD trends during 2000/01-2019/20 were analysed and cases between during February-June 2020 were linked with laboratory-confirmed SARS-CoV-2 infections. Multivariable logistic regression was used to assess risk factors for death. RESULTS: IPD incidence in 2019/20 (7.6/100,000; n=3,964) was 30% (IRR 0.70, 95%CI, 0.18-2.67) lower compared to 2018/19 (10.9/100,000; n=5,666) with large reductions observed across all age-groups during March-June 2020. The serotypes responsible for IPD during 2019/20 were similar to previous years. There were 160,886 SARS-CoV-2 and 1,137 IPD cases during February-June 2020, including 40 IPD/COVID-19 (0.025% [95%sCI, 0.018-0.034] of SARS-CoV-2 infections; 3.5% [95%CI, 2.5-4.8] of IPD cases), 21 with COVID-19 diagnosed 3-27 days after IPD and 27 who developed COVID-19 ≥28 days after IPD. Case-fatality rates (CFR) were 63.2% (25/40), 47.6% (10/21) and 33.3% (9/27), respectively (p<0.001). In addition to an independent association with increasing age and pneumococcal serotype group, CFR was 7.8-fold (95% CI, 3.8-15.8) higher in those with IPD/COVID-19 co-infection and 3.9-fold (95% CI, 1.4-10.7) higher in patients who developed COVID-19 3-27 days after IPD compared to patients with IPD only. CONCLUSIONS: Large declines in IPD were observed following COVID-19 lockdown in England. IPD/COVID-19 confections were rare but associated with high CFR, mainly in older adults. The rarity, age distribution and serotype distribution of IPD/SARS-CoV-2 coinfections does not support wider extension of pneumococcal vaccination.

Viral respiratory tract infections usually predispose to secondary bacterial infections which are associated with high morbidity and mortality, especially during pandemics [1, 2] . The association between Streptococcus pneumoniae and influenza, for example, is welldescribed, and has important implications because there are effective vaccines against the major pneumococcal serotypes causing invasive disease [3, 4] . Coronavirus disease 2019 , the disease caused by SARS-CoV-2, typically manifests as a respiratory tract infection and presents with fever and cough [5] , which may progress to severe pneumonia, multi-organ failure and death, especially in older adults and those with underlying comorbidities [6] [7] [8] . Bacterial co-infection with COVID-19, however, appears to be uncommon [9] [10] [11] . A meta-analysis of mainly small case series estimated that 3.5% of COVID-19 patients had a bacterial co-infection and 14.3% had a secondary bacterial infection [12] . These infections occurred mainly intensive care patients, with no particular pathogen predominating [12] .

In the United Kingdom, the first imported cases of COVID-19 were reported at the end of January 2020 and endemic transmission in late February, with cases increasing rapidly from early March and peaking in mid-April before declining [13] . In response, the UK implemented national lockdown measures on 23 March 2020 with a stay-at-home order for all but essential travel and work [14] . The reduced social mixing resulting from the lockdown is likely to have affected the incidence of many infectious diseases in addition to SARS-CoV-2 [15] .

In England, Public Health England is responsible for enhanced national surveillance of invasive pneumococcal disease (IPD) and COVID-19. We used multiple national surveillance data sources to investigate the impact of the COVID-19 pandemic and the consequent lockdown on IPD, to estimate the risk of SARS-CoV-2 and IPD co-infection and to describe the demographics, responsible serotypes, comorbidity status, clinical features and outcomes of patients with IPD/COVID-19 co-infection during the first wave of A c c e p t e d M a n u s c r i p t 6 pandemic in England. We also assessed the potential role of pneumococcal vaccines in reducing IPD morbidity and mortality during the COVID-19 pandemic.

In the UK, the 13-valent pneumococcal conjugate vaccine (PCV13) replaced the 7-valent vaccine (PCV7) in 2010 and, until recently, was offered to infants at 8 and 16 weeks of age, with a booster at 1 year [16] . From 01 January 2020, a reduced infant 1+1 infant immunisation schedule at 12 weeks and 1 year was implemented in the UK [17] . In addition, children aged ≥2 years and adults with underlying comorbidities that predispose them to IPD and all adults aged ≥65 years are offered a single dose of 23-valent pneumococcal polysaccharide vaccine (PPV23) [18] .

PHE conducts national IPD surveillance in England [19] . Briefly, hospital laboratories electronically report invasive pneumococcal infections to PHE using the Second-Generation Surveillance System (SGSS) and submit pneumococcal isolates to the PHE national reference laboratory for confirmation and serotyping. Confirmed cases are followed-up by requesting general practitioner to complete a surveillance questionnaire on immunisation history, comorbidities, clinical presentations, complications and outcomes. A final reconciled database containing laboratory-confirmed IPD cases during the 2000/01 to 2019/20 epidemiological years (July to June, 20 years) was used for this analysis.

SGSS also contains reports of laboratory-confirmed SARS-CoV-2 infections in England. In the UK, SARS-CoV-2 tests are performed through different routes called "Pillars" [20] . In Pillar 1, SARS-CoV-2 RT-PCR tests are undertaken on respiratory swabs by PHE laboratories and NHS hospitals for those with a clinical need and for health and care workers. This group was prioritised for SARS-CoV-2 testing by RT-PCR during the first A c c e p t e d M a n u s c r i p t 7 pandemic wave, with minimal virus testing in the community. Positive results from Pillar 1 testing were linked with IPD cases from 01 February to 30 June 2020 (5 months) using full name, sex, birthdate, reporting hospital, site and date of sample. IPD and SARS-CoV-2 cases confirmed in June 2020 were linked with cases until 31 July 2020. Deaths were confirmed using the patient demographic service, an online national database which holds demographic data and death status for NHS patients. 

Data were analysed using Stata v.15.0 (StataCorp, Tx), Corrected annual IPD incidence by epidemiological year and serotype group (PCV13, PPV23, non-PPV23) was calculated as previously described, adjusting for missing proportion of isolates serotyped and missing age, [19] 

There were large declines in IPD incidence across all age-groups during 2019/20 in England Both IPD and SARS-CoV-2 incidence were lowest in children during the 5-month surveillance and increased with age ( Table 2) . IPD/COVID-19 coinfections were identified in A c c e p t e d M a n u s c r i p t 10 0.025% (40/160,886; 95%CI, 0.018-0.034%) of patients with confirmed SARS-CoV-2 infection and 3.5% of IPD (40/1,137; 95%CI, 2.5-4.8%) cases. There were no IPD/COVID-19 co-infections in children. The risk of IPD/COVID-19 coinfection increased with age among IPD patients but to a lesser extent than IPD alone or SARS-CoV-2 alone (Table 2) (Table 3 ).

The COVID-19 pandemic and subsequent lockdown measures were associated a large decline in IPD cases in England. The 30% decline in IPD incidence was observed across all age groups and for all pneumococcal serotype groups. Among 160,886 laboratory-confirmed SARS-CoV-2 infections confirmed in a healthcare setting, we found only 88 individuals who developed both IPD and COVID-19 during the first wave of the epidemic and only 40 IPD/COVID-19 coinfections. Contrary to our hypothesis that SARS-CoV-2 infection might predispose to secondary pneumococcal infection, we found that patients were more likely to develop COVID-19 after IPD or as a separate episode ≥28 days after IPD. Those with IPD/COVID-19 coinfection had very high CFR, which decreased with increasing interval between the two infections. pandemic [15] . Interestingly, we observed significant reductions in IPD cases in older adults,

including ≥85 year-olds, at a time when large numbers of COVID-19 cases and deaths were reported in these age-groups [21] . The frail and elderly are at increased risk of both IPD and COVID-19 and both infections are individually associated with high CFR in this vulnerable age-group [18] . The inverse trend of decreasing IPD and increasing SARS-CoV-2 infections in older adults likely reflects differences in the source of infection and efficiency of transmission for the two pathogens. In particular, young children are considered to be the main reservoirs and source of pneumococcal infections [22] , and it is likely the shielding of older adults, especially from children, during lockdown reduced their risk of IPD but not from COVID-19 which was mainly acquired from other adults, as evidenced in the extensive COVID-19 outbreaks in care homes which were driven mainly by cross-infection between residents and staff [23] .

We found very few pneumococcal coinfections associated with SARS-CoV-2 in our cohort.

Interestingly, we did not identify any IPD/COVID-19 cases in children; since blood cultures are almost exclusively taken in hospital, children with IPD would have been tested for SARS-CoV-2 infection when they presented to hospital. This is consistent with the published case series, systematic reviews and meta-analyses which have so far not identified any patients with SARS-CoV-2 and pneumococcal co-infection [12] . There are limited data on bacterial coinfections with MERS or SARS [11] , but reports of bacterial coinfections with influenza range between 2-65%, with S. pneumoniae being the most common co-infecting bacteria, M a n u s c r i p t 12 accounting for 35% (95%CI, 14%-56%) of infections in one systematic review [1] . During the influenza A(H1N1) pandemic, when there were no lockdown measures or school closures in England, data linkage similar to our current analysis identified pneumococcal co-infection rates of 8% (10/125) in <15 year-olds, 11% (33/305) in 15-44 year-olds, 4% (33/858) in ≥45

year-olds and 6% (76/1,288) of IPD cases [24] . There is currently sufficient evidence to strengthen and potentially expand pneumococcal vaccination to reduce the risk of secondary pneumococcal infections associated with influenza and particularly during influenza pandemics [3, 25] . In contrast, the very low risk, wide age range and distribution of pneumococcal serotypes causing IPD in patients with IPD/COVID-19 coinfections does not support wider immunisation with any of the currently available pneumococcal vaccines. It is, however, important to maintain high pneumococcal immunisation rates to continue to protect those who are at increased risk of pneumococcal disease after the lockdown is eased Additionally, the low overall risk of bacterial coinfections also predicates judicious use of empiric antimicrobials in patients hospitalised with COVID-19. Up to three-quarters of patients hospitalised with COVID-19 in England receive empiric antibiotics despite the low risk of bacterial coinfections [9] . Unnecessary and widespread empiric antibiotic overuse can predispose to hospital-acquired, potentially multidrug-resistant secondary Gram-negative bacterial as well as fungal infections, which significantly increasing the risk of a fatal outcome [26, 27] .

In our cohort, CFR was 63.2% in patients with IPD/COVID-19 coinfection, which is significantly higher than that reported in older adults after IPD only [18] or COVID-19 only [28] , and suggests a potential synergistic effect between the two pathogens, as has been described for pneumococcal/influenza coinfections [29] . Furthermore, in addition to the 40 coinfections, we also identified 21 other patients who developed COVID-19 3-27 days after being hospitalised with IPD and 10 (47.6%) died. It is possible that at least some of these patients had IPD/COOVID-19 coinfection but our finding that 11 of the 15 IPD patients with confirmed COVID-19 at 3-14 days after IPD had negative swabs for SARS-CoV-2 when they A c c e p t e d M a n u s c r i p t 13 were hospitalised for IPD supports secondary and potentially nosocomially-acquired SARS-CoV-2 infection. This highlights the importance of maintaining stringent infection control practices in hospital [30, 31] , especially for frail and elderly adults, who may be hospitalised with a minor illness but could succumb to hospital-acquired COVID-19 [32, 33] . Finally, the finding that a third of patients who developed COVID-19 more than 14 days after their IPD episode died within 30 days of their subsequent SARS-CoV-2 infection highlights the vulnerability of this group of patients, most of whom were elderly and with multiple comorbidities.

The strength of this study lies in the availability and rapid cross-linking of multiple national data sources alongside long-term enhanced national surveillance of vaccine-preventable infections in England. In the UK, blood cultures are invariably performed in patients who attend hospital with suspected invasive bacterial infection. We, therefore, only linked IPD cases with Pillar 1 SARS-CoV-2 tests that were performed in a healthcare setting because we hypothesised that all IPD cases would have been hospitalised and tested for SARS-CoV-2 infection on admission. There was also very limited testing for SARS-CoV-2 in the community during the first wave of the epidemic in England. Additionally, since unwell individuals were more likely to have been referred directly to hospital instead of being assessed in primary care, they were unlikely to have been have been tested for SARS-CoV-2 outside the hospital setting or prescribed oral antibiotics that might have resulted in negative blood cultures on admission. A limitation of our analysis is that we only included patients with IPD and, therefore, cannot comment on the risk of non-invasive pneumococcal infections, such as pneumonia. IPD is, however, a reliable proxy for non-invasive Future studies using urine serotype-specific pneumococcal antigen testing could potentially help assess the risk of non-invasive pneumococcal pneumonia in patients with COVID-19 [37] . Another limitation is that it was not possible to distinguish between coinfection and secondary bacterial infection because the patients were only tested for the virus and had blood cultures taken when they first presented to hospital with their IPD episode. Finally, some patients, especially the frail and elderly, were not admitted to hospital and died at home or in a care home [38] . Early in the pandemic, these cases were also not tested for SARS-CoV-2 and, since they were not hospitalised, would not have been investigated for bacterial coinfections. In one case series, up to 50% of patients with COVID-19 who died had a secondary bacterial infection [26] , although consistent with our findings, S. pneumoniae was not identified as a cause.

The COVID-19 pandemic and the lockdown that followed to stop the spread of SARS-CoV-2 was associated with large declines in IPD across all age groups. IPD/COVID-19 confections were rare but associated with high CFR mainly in older adults. Secondary COVID-19 in patients hospitalised with IPD was also associated with high CFR, highlighting the 

This study was internally funded by PHE. The authors had sole responsibility for the study design, data collection, data analysis, data interpretation, and writing of the report. The authors are all employed by PHE, the study funder, which is a public body -an executive agency of the Department of Health. The corresponding author had full access to all the data in the study and final responsibility for the decision to submit for publication. A c c e p t e d M a n u s c r i p t 28 Figure 4 

The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses

Rate and influence of respiratory virus co-infection on pandemic (H1N1) influenza disease

Pneumococcal pneumonia and influenza: a deadly combination

The role of bacterial vaccines in the prevention of influenza mortality

Clinical characteristics, laboratory findings, radiographic signs and outcomes of 61,742 patients with confirmed COVID-19 infection: A systematic review and meta-analysis

The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study

Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis

Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis

Co-infections: potentially lethal and unexplored in COVID-19

Co-infections in people with COVID-19: a systematic review and meta-analysis

Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing

Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis

Weekly Coronavirus Disease 2019 (COVID-19) Surveillance Report: Summary of COVID-19 surveillance systems

Prime Minister's Office. Prime Minister's statement on coronavirus (COVID-19): 23

Impact of COVID-19 pandemic and the lockdown on invasive meningococcal disease

Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study

Summary of evidence to reduce the current two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate vaccine in the national immunisation programme in the United Kingdom

Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and Wales

Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study

COVID-19 testing data: methodology note

Excess all-cause mortality during the COVID-19 pandemic in Europe -preliminary pooled estimates from the EuroMOMO network

Estimating the contribution of different age strata to vaccine serotype pneumococcal transmission in the pre vaccine era: a modelling study

INVESTIGATION OF SARS-CoV-2 OUTBREAKS IN SIX CARE HOMES IN LONDON

EClinicalMedicine. 2020

Increase in invasive Streptococcus pyogenes and Streptococcus pneumoniae infections in England

Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study

Age-Related Morbidity and Mortality among Patients with COVID-19

Lethal Synergism between Influenza and Streptococcus pneumoniae

Nosocomial infections among patients with COVID-19, SARS and MERS: a rapid review and meta-analysis

Nosocomial transmission of COVID-19: a retrospective study of 66 hospital-acquired cases in a London teaching hospital

Nosocomial outbreak of SARS-CoV-2 infection in a haematological unit -High mortality rate in infected patients with haematologic malignancies

COVID-19: a retrospective cohort study with focus on the over-80s and hospital-onset disease

Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: a modelling study

A systematic review of chest imaging findings in COVID-19

CT Manifestations and Clinical Characteristics of 1115 Patients with Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-analysis

Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia

England and Wales see 20 000 excess deaths in care homes

A c c e p t e d M a n u s c r i p t 23 Table 3 . Multivariable logistic regression to assess independent risk factors for death within 28 days of of the last infection in patients with invasive pneumococcal disease (IPD) and COVID-19 within 28 days of each other compared to those with IPD only. Patients who developed COVID-19 more than 28 days after IPD were not included in the analysis